$550 million for Phase III trial of pulmonary TB vaccine

29 June 2023

A decades-long program to develop the first new vaccine for pulmonary tuberculosis in a century has received a half-billion dollar funding boost.

British drugmaker GSK (LSE: GSK) has been working on the jab, dubbed M72, since it picked up rights to the candidate through its 2005 purchase of American biotech Corixa.

While the vaccine has shown 54% effectiveness in a Phase II trial enrolling around 3,500 people in southern Africa, the company has until now not considered a larger study to be commercially viable.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK